CUBE vs TARS · P/E 25, rev $1.07B vs rev $183.0M
CubeSmart (CUBE) versus Tarsus Pharmaceuticals Inc (TARS) — a side-by-side from cached financials, not a winner call.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Tarsus Pharmaceuticals Inc (TARS) is a biotechnology company listed on NASDAQ.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Latest reported TARS revenue for 2024-12-31 was $183.0M. Net income was -$115.6M. Revenue was up 948.6% from 2023-12-31 to 2024-12-31. TARS currently screens at market cap $2.66B.
CUBE currently screens at market cap $9.69B and trailing P/E 25.0. TARS currently screens at market cap $2.66B.
Not investment advice. Open the CUBE and TARS stock pages for the full models.
Not investment advice.